Medicare Enrolled

Dr. Mona Iversen, M.D.

Rheumatology · Houston, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
1701 SUNSET BLVD, Houston, TX 77005
7135265511
In practice since 2008 (17 years)
NPI: 1720249055 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Iversen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Iversen? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Iversen

Dr. Mona Iversen is a rheumatology in Houston, TX, with 17 years in practice. Based on federal Medicare data, Dr. Iversen performed 98,591 Medicare services across 1,388 unique beneficiaries.

Between the years covered by Open Payments, Dr. Iversen received a total of $18,621 from 32 pharmaceutical and/or device companies across 1069 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Iversen is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice▲ Top 16% volume in TX$ $18,621 industry payments

Medicare Practice Summary

Medicare Utilization ↗
98,591
Medicare services
Top 16% in TX for rheumatology
1,388
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,799 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)37,600$4$5
Romosozumab injection (Evenity) for osteoporosis24,150$8$10
Denosumab injection (Prolia/Xgeva)12,960$18$24
Abatacept infusion (Orencia)11,725$34$43
Golimumab infusion (Simponi Aria)7,851$10$13
Infliximab infusion (Remicade)1,800$26$34
Drug injection, under skin or into muscle638$11$14
Steroid injection (triamcinolone)585$1$1
Office visit, established patient (30-39 min)276$95$130
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less230$52$65
Office visit, established patient (20-29 min)206$67$92
New patient office visit (45-59 min)133$128$170
Joint injection, major joint93$57$89
Calculation of trabecular bone score (tbs) using imaging data with interpretation and report on fracture risk73$31$43
Bone density scan (DEXA)72$38$39
Administration of chemotherapy into vein, each additional hour62$23$29
Telephone medical discussion with physician, 21-30 minutes55$105$131
Administration of chemotherapy into vein, 1 hour or less47$107$133
Aspiration and/or injection of fluid from small joint35$43$70
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
21.9% high complexity
77.3% medium
0.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$18,621
Total received (2018-2024)
Avg $2,660/year across 7 years
Top 18% in TX for rheumatology
32
Companies
1,069
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,556 (99.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$65 (0.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,007
2023
$2,796
2022
$1,955
2021
$2,202
2020
$2,782
2019
$2,923
2018
$2,956

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$3,372
Amgen Inc.
$3,100
AbbVie Inc.
$1,371
Novartis Pharmaceuticals Corporation
$1,278
E.R. Squibb & Sons, L.L.C.
$1,201
Janssen Biotech, Inc.
$1,076
UCB, Inc.
$958
AbbVie, Inc.
$938
Horizon Therapeutics plc
$880
PFIZER INC.
$556
Aurinia Pharma U.S., Inc.
$555
GENZYME CORPORATION
$488
Genentech USA, Inc.
$483
AstraZeneca Pharmaceuticals LP
$411
Lilly USA, LLC
$410
Mallinckrodt Enterprises LLC
$279
Horizon Pharma plc
$193
Celgene Corporation
$185
Mallinckrodt Hospital Products Inc.
$169
GlaxoSmithKline, LLC.
$151
TerSera Therapeutics LLC
$130
SOBI, INC
$87
SANOFI-AVENTIS U.S. LLC
$73
MEDEXUS PHARMA, INC.
$67
Boehringer Ingelheim Pharmaceuticals, Inc.
$63
MEDAC PHARMA, INC.
$41
Merck Sharp & Dohme Corporation
$26
Mallinckrodt LLC
$19
Hikma Pharmaceuticals USA
$17
Sandoz Inc.
$16
Zyla Life Sciences
$14
TESARO, Inc.
$11
Top 3 companies account for 42.1% of total payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · BENLYSTA · Bimzelx · CHANTIX · COSENTYX · CYLTEZO · Cimzia · DUEXIS · EVENITY · Enbrel · FORTEO · HUMIRA · HYRIMOZ · Humira · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · Mitigare · OFEV · ORENCIA · Otezla · PENNSAID · PNEUMOVAX 23 · Prolia · Quzyttir · RAYOS · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · TALTZ · TAVNEOS · TREMFYA · VIMOVO · XELJANZ · ZEJULA · ZORVOLEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $19 per 100 Medicare services performed
Looking for a rheumatology in Houston?
Compare rheumatologys in the Houston area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
81
Per 100K population
1.7
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
1.6 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Iversen is a mixed practice specialist, with above-average Medicare volume (top 16% in TX), and high industry engagement (low-engagement, top 18%), with 17 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Iversen experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Iversen performed 37,600 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Iversen receive payments from pharmaceutical companies?
Yes. Dr. Iversen received a total of $18,621 from 32 companies across 1,069 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Iversen's costs compare to other rheumatologys in Houston?
Dr. Iversen's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Iversen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →